Stock of the day: Pro Medicus
Discover why Pro Medicus (ASX: PME) is captivating investors with a record-breaking $330 million contract, strong momentum, and analyst upgrades despite valuation concerns.
(AI video summary)
This video was created on 4 December for IG audiences by ausbiz.
ASX code: PME
Insider moves and analyst upgrades
Pro Medicus continues to capture market attention, following news that its co-founders, Dr Sam Hupert and Anthony Hall, do not plan to sell additional shares in the foreseeable future. This announcement comes after the co-founders each sold 1 million Pro Medicus shares, representing 4% of their holdings, in a regular six-month pattern.
Adding to the excitement, Bell Potter upgraded its price target for Pro Medicus by almost 100%, now valuing the stock at $260. Despite the upgrade, the stock has already surpassed this level, reflecting strong market confidence. Bell Potter's analysts acknowledged their previous underestimation of the company's value, highlighting significant contract upgrades and market leadership as key drivers.
Record-breaking contracts
Pro Medicus recently signed a landmark 10-year, $330 million contract with one of the largest hospital systems in the United States. This deal follows a trend of exponentially growing contracts, reflecting the company’s success in transitioning from academic hospitals to larger public systems.
While Morgans raised its price target to $225, well below the current share price, the firm described the latest contract as 'shockingly large,' underscoring Pro Medicus’ ability to secure significant deals.
A high-quality yet expensive stock
According to Michael, a portfolio manager and long-time holder of Pro Medicus, the company remains a high-quality business with impressive growth figures such as revenues up 30% – 40%, and earnings are climbing at a similar pace. However, he admits that the valuation seems extreme, with a price-to-earnings (P/E) ratio far above historical norms.
Michael shared that Pro Medicus has historically provided opportunities for investors to buy during pullbacks of 30% – 50%, but recent performance has made such corrections rare. While he holds a 'hold' rating on the stock, he recommends waiting for a significant weakness before adding more.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Explore the markets with our free course
Discover and learn how the range of markets you can trade on with IG Academy's online course – ‘Introducing the financial markets’.
Put learning into action
Try out what you’ve learned in this shares strategy article risk-free in your demo account.
Ready to trade shares?
Put the lessons in this article to use in a live account – upgrading is quick and easy.
- Trade on over 10,000 popular global stocks
- Protect your capital with risk management tools
- React to breaking news with out-of-hours trading on 70 key US stocks
Inspired to trade?
Put your new knowledge into practice. Log in to your account now.
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.